A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

Recruitment Status
ACTIVE, NOT RECRUITING
(See Contacts and Locations)Verified March 2026 by Janssen Research & Development, LLC
Sponsor
Janssen Research & Development, LLC
Information Provided by (Responsible Party)
Janssen Research & Development, LLC
Clinicaltrials.gov Identifier
NCT06095115
Other Study ID Numbers:
77242113PSO3001
First Submitted
October 17, 2023
First Posted
October 22, 2023
Last Update Posted
April 12, 2026
Last Verified
March 2026

ClinicalTrials.gov processed this data on April 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Plaque Psoriasis
Drug: JNJ-77242113Drug: JNJ-77242113

Study Design

Study TypeInterventional
Actual Enrollment684 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingDouble
Primary PurposeTreatment
Official TitleA Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment
Study Start DateOctober 11, 2023
Actual Primary Completion DateJuly 28, 2024
Actual Study Completion Date10mos 1w from now

Groups and Cohorts

Group/CohortIntervention/Treatment
JNJ-77242113
Adolescent and adult participants will receive JNJ-77242113 from Week 0 through Week 156. At Week 24, adult participants who are psoriasis area and severity index (PASI) 75 or investigator global assessment (IGA) score of 0 or 1 responders (that is, those who achieve an IGA score of 0 or 1 and have \>=2-grade improvement from baseline) will be re-randomized either to continue JNJ-77242113 or to placebo (and will be retreated with JNJ-77242113 upon loss of \>=50% of their Week 24 PASI improvement). Adult participants identified as both PASI 75 and IGA 0 or 1 score non-responders will continue to receive JNJ-77242113 through Week 52. From Week 52 to Week 156, all adult participants will receive JNJ-77242113. Adolescents will not participate in re-randomization regardless of their PASI score or IGA score at Week 24. Adolescents will continue to receive JNJ-77242113 from Week 0 through Week 156.
Drug: JNJ-77242113
JNJ-77242113 will be administered orally.
Placebo
Adolescent and adult participants will receive JNJ-77242113 matching placebo from Week 0 to Week 16. Participants will cross-over to receive JNJ-77242113 from Week 16 through Week 156.
Drug: JNJ-77242113
JNJ-77242113 will be administered orally.

Outcome Measures

Primary Outcome Measures
  1. Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>= )2-Grade Improvement From Baseline to Week 16
    Percentage of participants who achieve an IGA score of 0 or 1 and \>=2-grade improvement from baseline to Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  2. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
    Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Secondary Outcome Measures
  1. Percentage of Participants Achieving an IGA Score of 0 at Week 16
    Percentage of participants who achieve an IGA score of 0 at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  2. Percentage of Participants Achieving PASI 75 Response at Weeks 4 and 16
    Percentage of participants achieving PASI 75 response (\>=75% improvement in PASI from baseline) at Weeks 4 and 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  3. Percentage of Participants Achieving PASI 90 Response at Week 8
    Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 8 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  4. Percentage of Participants Achieving PASI 100 Response at Week 16
    Percentage of participants achieving PASI 100 response (\>=100% improvement in PASI) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  5. Percentage of Participants Achieving Scalp-specific Investigator Global Assessment (ss-IGA) Score of 0 or 1 and >=2 Grade Improvement Baseline to Week 16
    Percentage of participants achieving ss-IGA score of 0 or 1 and \>=2 grade improvement baseline to Week 16 will be reported. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).
  6. Percentage of Participants Achieving Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score of 0 at Weeks 8 and 16
    Percentage of participants achieving PSSD symptom score of 0 at Weeks 8 and 16 will be reported. The PSSD includes patient-reported outcome (PRO) questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  7. Percentage of Participants Achieving >=4-Point Improvement From Baseline in PSSD Itch Score to Weeks 4 and 16
    Percentage of participants achieving \>=4-Point improvement from baseline in PSSD itch score to Weeks 4 and 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  8. Time to Loss of PASI 75
    Time to loss of PASI 75 will be reported. Loss of PASI 75 response is defined as \<75% improvement in PASI from Week 24 up to Week 52 in an adult participant who had achieved \>=75% improvement in PASI from baseline at Week 24. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. A PASI 75 response represents at least a 75% improvement from baseline in the PASI score.
  9. Time to Loss of PASI 90
    Time to loss of PASI 90 will be reported. Loss of PASI 90 response is defined as \<90% improvement in PASI from Week 24 up to Week 52 in an adult participant who had achieved \>=90% improvement in PASI from baseline at Week 24. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. A PASI 90 response represents at least a 90% improvement from baseline in the PASI score.
  10. Number of Participants with Treatment-emergent Adverse Events (AEs)
    An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study. Treatment-emergent AEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
  11. Number of Participants with Treatment-emergent Serious Adverse Events (SAEs)
    A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly. Treatment-emergent SAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.
  12. Change from Baseline in Body Surface Area (BSA) at Week 16
    Change from baseline in BSA to Week 16 will be reported. BSA is a commonly used measure of extent of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed (that is, plaque psoriasis).
  13. Change from Baseline in PASI Total Score to Week 16
    Change from baseline in PASI total score to Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  14. Percent Improvement in PASI Score From Baseline to Week 16
    Percent improvement in PASI score from baseline to Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  15. Percentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and at Least a 2-grade Improvement in Genital Psoriasis From Baseline to Week 16
    Percentage of participants achieving a sPGA-G Score of 0 or 1 and at Least a 2-grade Improvement in genital psoriasis from baseline to Week 16 will be reported. The sPGA-G is a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5).
  16. Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement at Week 16
    Percentage of participants achieving a hf-PGA score of 0 or 1 and at least a 2-grade improvement at Week 16 will be reported. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3), and severe (4).
  17. Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16
    Percent change from baseline in mNAPSI score at Week 16 will be reported. The mNAPSI is an index used for assessing and grading the severity of nail psoriasis. Each of the participant's 10 fingernails are evaluated for 7 features. The first3 features are each scored from 0 to 3 in severity and are (1) onycholysis and oil-drop dyschromia, (2) pitting, and (3) nail plate crumbling. The next 4 features are scored 0 - absent or 1 - present and are (1) leukonychia, (2) splinter hemorrhages, (3) nail bed hyperkeratosis, and (4) red spots in the lunula. The score ranges from 0 to 13 per nail and 0 to 130 for all fingernails.
  18. Percent of Participants Achieving Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16
    Percent of participants achieving f-PGA score of 0 or 1 at Week 16 will be reported. The f-PGA is used to evaluate the current status of a participant's fingernail psoriasis on a scale of 0 to 4 (clear \[0\], minimal \[1\], mild \[2\], moderate \[3\], or severe \[4\]).
  19. Change From Baseline in PSSD Symptom Score to Week 16
    Change from baseline in PSSD symptom score to Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  20. Change From Baseline in PSSD Sign Score to Week 16
    Change from baseline in PSSD sign score to Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  21. Percentage of Participants Achieving PSSD Sign Score of 0 at Week 16
    Percentage of participants achieving PSSD sign score of 0 at Week 16 will be reported. The PSSD includes PRO questionnaire designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  22. Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16
    Percentage of participants achieving GenPs-SFQ Item 2 score of 0 or 1 at Week 16 will be reported. The GenPs-SFQ is a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (never \[0\], rarely \[1\], sometimes \[2\], often \[3\], or always \[4\]).
  23. Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16
    Percentage of participants achieving DLQI score of 0 or 1 at Week 16 will be reported. The DLQI is a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  24. Change From Baseline in Total DLQI Score at Week 16
    Change from baseline in total DLQI score at Week 16 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  25. Change from Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16
    Change from baseline in domain scores of the PROMIS-29 score at Week 16 will be reported. The PROMIS-29 is a 29-item generic HRQoL survey, assessing each of the 7 PROMIS domains(depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. The questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.
  26. Percentage of Participants Achieving Children's Dermatology Life Quality Index (CDLQI) Score of 0 or 1 at Week 16
    Percentage of participants achieving CDLQI score of 0 or 1 at Week 16 will be reported. The CDLQI is an adapted version of the DLQI for the pediatric population and will be utilized in the adolescent population in this study. The adaption and validation of the CDLQI was undertaken by the original developer of the DLQI to ensure it addressed the specific needs of the pediatric population. The CDLQI is a 10-item instrument that has 4 item response options and a recall period of 1 week. Higher scores indicate greater impact on HRQoL. The instrument is designed for use in children is self-explanatory and can be simply handed to the participant who is asked to fill it in with the help of the child's parent or caregiver.
  27. Change From Baseline in CDLQI at Week 16
    Change from baseline in CDLQI at Week 16 will be reported. The CDLQI is an adapted version of the DLQI for the pediatric population and will be utilized in the adolescent population in this study. The adaption and validation of the CDLQI was undertaken by the original developer of the DLQI to ensure it addressed the specific needs of the pediatric population. The CDLQI is a 10-item instrument that has 4 item response options and a recall period of 1 week. Higher scores indicate greater impact on HRQoL. The instrument is designed for use in children is self-explanatory and can be simply handed to the participant who is asked to fill it in with the help of the child's parent or caregiver.
  28. Change From Baseline in the Domain Scores of the PROMIS-25 Pediatric Score at Week 16
    Change from baseline in the domain scores of the PROMIS-25 pediatric score at Week 16 will be reported. The PROMIS-25 will be utilized in the adolescent population and is a 25-item generic HRQoL survey. Six PROMIS domains (physical function mobility, anxiety, depressive symptoms, fatigue, peer relationships, pain interference) are each assessed with 4 questions. There is also one 11-point rating scale for pain intensity. The instrument is designed for use in ages 8-17 years of age and can be self-administered.
  29. Percentage of Participants Achieving IGA Score of 0 at Week 52
    Percentage of participants achieving IGA score of 0 at Week 52 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  30. Percentage of Participants Achieving PASI 100 Response at Week 52
    Percentage of participants achieving PASI 100 response (100% improvement in PASI) at Week 52 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  31. Time to Loss of IGA 0 to 1 Response
    Time to loss of IGA 0 to 1 response will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  32. Percentage of Adolescent Participants Achieving IGA Score of 0 or 1 and >=2 Improvement From Baseline to Week 52
    Percentage of adolescent participants achieving IGA score of 0 or 1 and IGA score \>=2 from baseline to Week 52 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  33. Percentage of Adolescent Participants Achieving PASI 75 Response at Week 52
    Percentage of adolescent participants achieving PASI 75 response (\>=75% improvement in PASI from baseline) at Week 52 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  34. Percentage of Adolescent Participants Achieving PASI 90 Response at Week 52
    Percentage of adolescent participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 52 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.

Eligibility Criteria

Ages Eligible for Study(Child, Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention
Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
Total investigator global assessment (IGA) \>=3 at screening and baseline
Candidate for phototherapy or systemic treatment for plaque psoriasis
A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test beta-human chorionic gonadotropin (beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention
Exclusion Criteria
Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
Major surgical procedures, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from a surgical procedure or has a surgical procedure planned during the time the participant is expected to participate in the study

Contacts and Locations

Sponsors and CollaboratorsJanssen Research & Development, LLC
Locations
Medical Dermatology Specialists | Phoenix Arizona, United States, 85006Johnson Dermatology | Fort Smith Arkansas, United States, 72916First OC Dermatology | Fountain Valley California, United States, 92708Center for Dermatology Clinical Research | Fremont California, United States, 94538Integrative Skin Science and Research | Sacramento California, United States, 95815Rady Childrens Hospital San Diego | San Diego California, United States, 92123Southern California Dermatology | Santa Ana California, United States, 92701Clinical Science Institute | Santa Monica California, United States, 90404Bioclinical Research Alliance Inc. | Miami Florida, United States, 33155Ziaderm Research LLC | North Miami Beach Florida, United States, 33162Forcare Clinical Research Inc | Tampa Florida, United States, 33613Skin Care Physicians of Georgia | Macon Georgia, United States, 31217Arlington Dermatology | Rolling Meadows Illinois, United States, 60008Endeavor Health | Skokie Illinois, United States, 60077Dundee Dermatology | West Dundee Illinois, United States, 60118Dawes Fretzin Clinical Research Group LLC | Indianapolis Indiana, United States, 46250Indiana Clinical Trial Center | Plainfield Indiana, United States, 46168Qualmedica Research | Owensboro Kentucky, United States, 42301Dermatology and Advanced Aesthetics | Lake Charles Louisiana, United States, 70605Allcutis Research 1 | Beverly Massachusetts, United States, 01915Michigan Center of Medical Research | Clarkston Michigan, United States, 48346Minnesota Clinical Study Center | New Brighton Minnesota, United States, 55112Skin Specialists | Omaha Nebraska, United States, 68144Allcutis Research | Portsmouth New Hampshire, United States, 03801Schweiger Dermatology Group | East Windsor New Jersey, United States, 08520Icahn School of Medicine at Mt. Sinai | New York New York, United States, 10029Wilmington Dermatology Center | Wilmington North Carolina, United States, 28405Oakview Dermatology | Athens Ohio, United States, 45701Optima Research | Boardman Ohio, United States, 44512Dermatologists of Central States LLC | Fairborn Ohio, United States, 45324Central Sooner Research | Oklahoma City Oklahoma, United States, 73170Oregon Medical Research Center | Portland Oregon, United States, 97201Oregon Dermatology and Research Center | Portland Oregon, United States, 97210The Pennsylvania Centre for Dermatology, LLC | Exton Pennsylvania, United States, 19341University of Pittsburgh Medical Center | Pittsburgh Pennsylvania, United States, 15213Medical University of South Carolina | Charleston South Carolina, United States, 29425Health Concepts | Rapid City South Dakota, United States, 57702Arlington Research Center, Inc. | Arlington Texas, United States, 76011The University of Texas Health Science Center at Houston | Bellaire Texas, United States, 77401Center for Clinical Studies 1 | Houston Texas, United States, 77004Texas Dermatology and Laser Specialists | San Antonio Texas, United States, 78218Center for Clinical Studies | Webster Texas, United States, 77598Springville Dermatology CCT Research | Springville Utah, United States, 84663Virginia Dermatology Skin Cancer Center Pllc | Norfolk Virginia, United States, 23502Frontier Derm Partners CRO, LLC | Mill Creek Washington, United States, 98012Premier Clinical Research | Spokane Washington, United States, 99202ARCIS Salud SRL Aprillus asistencia e investigacion | Buenos Aires , Argentina, C1406AGACentro Privado de Medicina Familiar | Buenos Aires , Argentina, C1417EYGDerma Internacional S A | Buenos Aires , Argentina, C1426Psoriahue | CABA , Argentina, C1425DKGCentro de Investigaciones Medicas Mar Del Plata | Mar del Plata , Argentina, B7600FYKInstituto De Especialidades De La Salud SRL | Rosario , Argentina, S2000DBSMR Medicina Reumatologica | San Fernando , Argentina, B1646Dr Rodney Sinclair Pty Ltd | East Melbourne , Australia, 3002The Alfred Hospital | Melbourne , Australia, 3004Kingsway Dermatology & Aesthetics | Miranda , Australia, 2228ISHI dermatology | Mitcham , Australia, 3132Royal Melbourne Hospital | Parkville , Australia, 3050Veracity Clinical Research | Woolloongabba , Australia, 4102Dermatology Research Institute Inc | Calgary Alberta, Canada, T2J 7E1Rejuvenation Dermatology Clinic Edmonton Downtown | Edmonton Alberta, Canada, T5J 3S9Dr. Chih ho Hong Medical | Surrey British Columbia, Canada, V3R 6A7Mediprobe Research Inc. | London Ontario, Canada, N5X 2P1Dr Wei Jing Loo Medicine Professional Corporation | London Ontario, Canada, N6H 5L5Ryan Clinical Research Inc | Newmarket Ontario, Canada, L3Y 5G8Canadian Dermatology Center | Toronto Ontario, Canada, M3B 0A7Toronto Research Centre | Toronto Ontario, Canada, M3H 5Y8FACET Dermatology | Toronto Ontario, Canada, M4C 1L1XLR8 Medical Research | Windsor Ontario, Canada, N8T 1E6Innovaderm Research Inc. | Montreal Quebec, Canada, H2X 2V1China Japan Friendship Hospital | Beijing , China, 100013Beijing Friendship Hospital Capital Medical University | Beijing , China, 100050Peking University Third Hospital | Beijing , China, 100191The Affiliated Hospital of Bengbu Medical College | Bengbu , China, 233099Hosp. of Chengde Medical University | Chengde , China, 067030Chengdu Second People's Hospital | Chengdu , China, 610017The First Hospital of Jiaxing | Jiaxing , China, 314001Qilu Hospital of Shandong University | Jinan , China, 250012Dermatology Hospital of Jiangxi Province | Nanchang , China, 330000Nanyang First People's Hospital | Nanyang , China, 473004Shanghai skin disease hospital | Shanghai , China, 200443Northeast International Hospital | Shenyang , China, 110016Union Hospital Tongji Medical College of Huazhong University of Science and Technology | Wuhan , China, 430022The Second Affiliated Hospital of Xi'an Jiaotong University | Xi'an , China, 710004Affiliated Hospital of Jiangsu University | Zhenjiang , China, 212001Hopital Prive d'Antony | Antony , France, 92160Centre Hospitalier Victor Dupouy | Argenteuil , France, 95107Fachklinik Bad Bentheim | Bad Bentheim , Germany, 48455Charite - Campus Mitte | Berlin , Germany, 10117Universitatsklinikum Bonn | Bonn , Germany, 53127Klinische Forschung Dresden GmbH | Dresden , Germany, 01069Hautzentrum Dulmen | Dülmen , Germany, 48249Privatpraxis Dr. Hilton & Partner | Düsseldorf , Germany, 40212Universitaetsklinikum Frankfurt | Frankfurt am Main , Germany, 60590Universitaetsklinikum Freiburg | Freiburg im Breisgau , Germany, 79104Derma-Study-Center Friedrichshafen GmbH | Friedrichshafen , Germany, 88045Universitaetsklinikum Heidelberg | Heidelberg , Germany, 69120Hautarztpraxis | Mahlow , Germany, 15831Universitaetsklinikum Muenster | Münster , Germany, 48149Klinikum Oldenburg | Oldenburg , Germany, 26133Hautarztpraxis Mortazawi | Remscheid , Germany, 42897Universitaetsklinik Tuebingen | Tübingen , Germany, 72076Hautarztpraxis 2 | Witten , Germany, 58453CentroDerm GmbH | Wuppertal , Germany, 42287Pecsi Tudomanyegyetem | Borgyogyaszati Klinika , Hungary, 7632Obudai Egeszsegugyi Centrum Kft | Budapest , Hungary, 1036Derma-B Kft | Debrecen , Hungary, 4031Debreceni Egyetem Klinikai Kozpont | Debrecen , Hungary, 4032Somogy Varmegyei Kaposi Mor Oktato Korhaz | Kaposvár , Hungary, 7400SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati és Allergologiai Klinika | Szeged , Hungary, 6720Allergo-Derm Bakos Kft. | Szolnok , Hungary, 5000Medmare Egeszsegugyi Es Szolgaltato Bt. | Veszprém , Hungary, 8200Azienda Di Rilievo Nazionale E Di Alta Specializzazione | Palermo , Italy, 90127Azienda Ospedaliero Universitaria di Parma | Parma , Italy, 43126Policlinico Tor Vergata | Roma , Italy, 00133Istituto Clinico Humanitas | Rozzano , Italy, 20089Teikyo University Hospital | Itabashi Ku , Japan, 173 8606Hospital of the University of Occupational and Environmental Health | Kitakyushu-shi , Japan, 807-8556Mito Kyodo General Hospital | Mito , Japan, 310 0015Nagoya City University Hospital | Nagoya , Japan, 467 8602Kindai University Hospital | Osaka Sayama Shi , Japan, 589 8511Tohoku University Hospital | Sendai , Japan, 980 8574Tokyo Medical University Hospital | Shinjuku , Japan, 160 0023Mie University Hospital | Tsu , Japan, 514 8507Osteo-Medic s.c A. Racewicz, J Supronik | Bialystok , Poland, 15-351Specderm Poznanska sp j | Bialystok , Poland, 15-375Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska | Elblag , Poland, 82 300Centrum Medyczne dr Rajzer Sp z o o | Krakow , Poland, 30 438Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna | Krakow , Poland, 30-002Centrum Medyczne Promed | Krakow , Poland, 31-411Dermed Centrum Medyczne Sp z o o | Lodz , Poland, 90-265Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna | Lodz , Poland, 90-338Dermodent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski S C | Osielsko , Poland, 86031SOLUMED Centrum Medyczne | Poznan , Poland, 60 529Clinical Research Center sp z o o MEDIC R s k | Poznan , Poland, 61 731Dorota Bystrzanowska High-Med. Przychodnia Specjalistyczna | Warsaw , Poland, 01 817Klinika Ambroziak Dermatologia | Warsaw , Poland, 02 953DERMMEDICA Sp.z o.o. | Wroclaw , Poland, 51 503Wro Medica | Wroclaw , Poland, 51 685Centrum Medyczne Oporow | Wroclaw , Poland, 52 416Korea University Ansan Hospital | Ansan-si , South Korea, 15355Chosun university hospital | Gwangju , South Korea, 61453CHA Bundang Medical Center, CHA University | Gyeonggi-do , South Korea, 13496Hallym University Sacred Heart Hospital | Gyeonggi-do , South Korea, 14068Asan Medical Center | Seoul , South Korea, 05505Hosp. Univ. Fundacion Alcorcon | Alcorcón , Spain, 28922Hosp. Gral. Univ. Dr. Balmis | Alicante , Spain, 03010Hosp Clinic de Barcelona | Barcelona , Spain, 08036Hosp. de La Santa Creu I Sant Pau | Barcelona , Spain, 08041Hosp. Univ. de Basurto | Bilbao , Spain, 48013Grupo Dermatologico Y Estetico Pedro Jaen | Madrid , Spain, 28002Hosp. Gral. Univ. Gregorio Maranon | Madrid , Spain, 28007Hosp. Univ. Son Espases | Palma de Mallorca , Spain, 07120Hosp. Clinico Univ. de Santiago | Santiago de Compostela , Spain, 15706Hosp. Virgen Macarena | Seville , Spain, 41009Hosp. de Manises | Valencia , Spain, 46940National Taiwan University Hospital Hsin Chu Branch | Hsinchu , Taiwan, 30059Kaohsiung Chang Gung Memorial Hospital | Kaohsiung City , Taiwan, 83301National Taiwan University Hospital | Taipei , Taiwan, 10048Mackay Memorial Hospital | Taipei , Taiwan, 10449Taipei Veterans General Hospital | Taipei , Taiwan, 11217Linkou Chang Gung Memorial Hospital | Taoyuan , Taiwan, 33382Hacettepe University Medical Faculty | Ankara , Turkey (Türkiye), 06230Gazi University Medical Faculty | Ankara , Turkey (Türkiye), 06560Erciyes University Medical Faculty | Kayseri , Turkey (Türkiye), 38039Ondokuz Mayis University | Samsun , Turkey (Türkiye), 55270London North West University Healthcare NHS Trust | Harrow , United Kingdom, HA1 3UJGuys and St Thomas NHS Foundation Trust | London , United Kingdom, SE1 9RTRoyal Berkshire Hospital | Reading , United Kingdom, RG1 5ANSalford Royal Hospital | Salford , United Kingdom, M6 8HD
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC